Testing two drugs together for NF2 tumors that are growing
Original title: Luvometinib in Combination With Serplulimab for NF2-Related Tumors
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test to see if the two drugs are safe in people.
Status: Not yet recruiting. It has not opened yet. Ask your care team to watch for it if it looks like a fit.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is checking whether two drugs, given together, are safe for people whose NF2 tumors are growing.
Who this trial is for. This trial is for people with NF2-related schwannomatosis whose tumors are growing. It tests two drugs given together, luvometinib and serplulimab. Everyone in the study gets both drugs. It runs at more than one center, and it is part of a larger NF2 research program called PRIME-NF2.
Where it stands. The trial has not reported results. It is measuring how safe the two drugs are, how well people handle them, and whether there are any early signs of benefit. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: If your tumors are growing and you have NF2-related schwannomatosis, this is one study you could ask your care team about. They can tell you if it makes sense for you. Joining a study is a decision to make with them.
What it doesn't mean: This does not mean these drugs work. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that you will be helped, and some people are not helped at all. This is not a promise of a cure.
Source: ClinicalTrials.gov, July 16, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.